These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3952554)

  • 1. Influence of mitotane on the hypoprothrombinemic effect of warfarin.
    Cuddy PG; Loftus LS
    South Med J; 1986 Mar; 79(3):387-8. PubMed ID: 3952554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction.
    Shovick VA; Rihn TL
    DICP; 1991 Jun; 25(6):598-600. PubMed ID: 1877267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.
    Nader N; Raverot G; Emptoz-Bonneton A; Déchaud H; Bonnay M; Baudin E; Pugeat M
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2165-70. PubMed ID: 16551731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical role of determination of plasma mitotane and its metabolites levels in patients with adrenal cancer: results of a long-term follow-up.
    Kasperlik-Zaluska AA; Cichocki A
    J Exp Ther Oncol; 2005; 5(2):125-32. PubMed ID: 16471038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer.
    Schteingart DE; Sinsheimer JE; Benitez RS; Homan DF; Johnson TD; Counsell RE
    Anticancer Res; 2012 Jul; 32(7):2711-20. PubMed ID: 22753730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium.
    Krstenansky PM; Jones WN; Garewal HS
    Clin Pharm; 1987 Oct; 6(10):804-6. PubMed ID: 3505843
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
    Theile D; Haefeli WE; Weiss J
    Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced hypoprothrombinemia with warfarin due to azithromycin.
    Rao KB; Pallaki M; Tolbert SR; Hornick TR
    Ann Pharmacother; 2004 Jun; 38(6):982-5. PubMed ID: 15084685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin.
    Silver BA; Bell WR
    Ann Intern Med; 1979 Mar; 90(3):348-9. PubMed ID: 426403
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture.
    Fang VS
    Cancer Res; 1979 Jan; 39(1):139-45. PubMed ID: 761184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chiral effects in adrenocorticolytic action of o,p'-DDD (mitotane) in human adrenal cells.
    Asp V; Cantillana T; Bergman A; Brandt I
    Xenobiotica; 2010 Mar; 40(3):177-83. PubMed ID: 20044879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.
    Ford MA; Anderson ML; Rindone JP; Jaskar DW
    J Clin Psychopharmacol; 1997 Apr; 17(2):110-2. PubMed ID: 10950474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review.
    Boven E; Vermorken JB; van Slooten H; Pinedo HM
    Cancer; 1984 Jan; 53(1):26-9. PubMed ID: 6360329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements.
    Robinson BG; Hales IB; Henniker AJ; Ho K; Luttrell BM; Smee IR; Stiel JN
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):437-44. PubMed ID: 2830062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased conversion of androgens to normal 17-ketosteroid metabolites as a result of treatment with o,p'-DDD.
    Hellman L; Bradlow HL; Zumoff B
    J Clin Endocrinol Metab; 1973 May; 36(5):801-3. PubMed ID: 4266860
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of o,p'-DDD therapy on plasma cholesterol in adrenal carcinoma.
    MOLNAR GD; NUNN SL; TAUXE WN
    Proc Staff Meet Mayo Clin; 1961 Nov; 36():618-20. PubMed ID: 14475247
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin.
    Lane G
    Ann Pharmacother; 1996; 30(7-8):884-5. PubMed ID: 8826581
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment with o,p'-DDD (mitotane) decreased cytochrome P-450, heme, and microsomal protein content in the dog adrenal cortex in vivo.
    Martz F; Straw JA
    Res Commun Chem Pathol Pharmacol; 1976 Jan; 13(1):83-92. PubMed ID: 1257603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.